Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 29,494 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 29,494 shares of Liquidia stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $60.13, for a total value of $1,773,474.22. Following the completion of the sale, the director owned 38,755 shares in the company, valued at approximately $2,330,338.15. This represents a 43.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Liquidia Trading Down 1.4%

Shares of LQDA traded down $0.88 during mid-day trading on Tuesday, hitting $60.10. 1,283,528 shares of the company’s stock traded hands, compared to its average volume of 1,696,211. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $5.34 billion, a P/E ratio of 429.32 and a beta of 0.41. The business’s 50-day moving average price is $42.53 and its 200-day moving average price is $37.56. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $62.30.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. As a group, sell-side analysts forecast that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wells Fargo & Company raised their price objective on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. Needham & Company LLC lifted their price target on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Finally, Wall Street Zen upgraded shares of Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Segall Bryant & Hamill LLC purchased a new position in Liquidia during the first quarter valued at $2,111,000. Bank of America Corp DE grew its stake in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Liquidia by 25.0% during the first quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock valued at $2,734,000 after acquiring an additional 14,485 shares in the last quarter. Empowered Funds LLC bought a new position in shares of Liquidia during the first quarter valued at $3,650,000. Finally, Eversept Partners LP raised its position in shares of Liquidia by 33.0% in the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).